Abstract
Paclitaxel (Taxol™), a naturally occurring antimitotic agent, has shown significant cell-killing activity against tumor cells through induction of apoptosis. The mechanism by which paclitaxel induces cell death is not entirely clear. Recent studies in our laboratory discovered that glucocorticoids selectively inhibited paclitaxel-induced apoptosis without affecting the ability of paclitaxel to induce microtubule bundling and mitotic arrest. This finding implies that apoptotic cell death induced by paclitaxel may occur via a pathway independent of mitotic arrest. Through analyses of a number of apoptosis-associated genes or regulatory proteins, we found that glucocorticoids and paclitaxel possess opposite regulatory role in the NF- κB / IκBα signaling pathway. Further studies indicate that paclitaxel activates IκB Kinase (IKK), which in turn causes degradation of IκBα and activation of NF-κB, whereas glucocorticoids antagonize paclitaxel-mediated NF-κB activation through induction of IκBα synthesis. These results suggest that the NF-κB / IκBα signaling pathway might play a critical role in the mediation or regulation of paclitaxel-induced cell death. On the other hand, since glucocorticoids (such as dexamethasone) are routinely used in the clinical application of paclitaxel to prevent hypersensitivity reactions and other adverse effects, the inhibitory action of glucocorticoids on paclitaxel-induced apoptosis also raises a clinically relevant question as to whether the pretreatment with glucocorticoids might interfere with the therapeutic efficacy of paclitaxel.
Keywords: paclitaxel, glucocorticoids, apoptosis, mitotic arrest, microtubules, kinase
Current Medicinal Chemistry
Title: Glucocorticoids Selectively Inhibit Paclitaxel-Induced Apoptosis: Mechanisms and Its Clinical Impact
Volume: 11 Issue: 4
Author(s): Weimin Fan, Meihua Sui and Yi Huang
Affiliation:
Keywords: paclitaxel, glucocorticoids, apoptosis, mitotic arrest, microtubules, kinase
Abstract: Paclitaxel (Taxol™), a naturally occurring antimitotic agent, has shown significant cell-killing activity against tumor cells through induction of apoptosis. The mechanism by which paclitaxel induces cell death is not entirely clear. Recent studies in our laboratory discovered that glucocorticoids selectively inhibited paclitaxel-induced apoptosis without affecting the ability of paclitaxel to induce microtubule bundling and mitotic arrest. This finding implies that apoptotic cell death induced by paclitaxel may occur via a pathway independent of mitotic arrest. Through analyses of a number of apoptosis-associated genes or regulatory proteins, we found that glucocorticoids and paclitaxel possess opposite regulatory role in the NF- κB / IκBα signaling pathway. Further studies indicate that paclitaxel activates IκB Kinase (IKK), which in turn causes degradation of IκBα and activation of NF-κB, whereas glucocorticoids antagonize paclitaxel-mediated NF-κB activation through induction of IκBα synthesis. These results suggest that the NF-κB / IκBα signaling pathway might play a critical role in the mediation or regulation of paclitaxel-induced cell death. On the other hand, since glucocorticoids (such as dexamethasone) are routinely used in the clinical application of paclitaxel to prevent hypersensitivity reactions and other adverse effects, the inhibitory action of glucocorticoids on paclitaxel-induced apoptosis also raises a clinically relevant question as to whether the pretreatment with glucocorticoids might interfere with the therapeutic efficacy of paclitaxel.
Export Options
About this article
Cite this article as:
Fan Weimin, Sui Meihua and Huang Yi, Glucocorticoids Selectively Inhibit Paclitaxel-Induced Apoptosis: Mechanisms and Its Clinical Impact, Current Medicinal Chemistry 2004; 11 (4) . https://dx.doi.org/10.2174/0929867043455990
DOI https://dx.doi.org/10.2174/0929867043455990 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances of Hepsin-Targeted Inhibitors
Current Medicinal Chemistry Peptide Sequence-Dominated Enzyme-Responsive Nanoplatform for Anticancer Drug Delivery
Current Topics in Medicinal Chemistry NOTCH Signaling as a Novel Cancer Therapeutic Target
Current Cancer Drug Targets Bortezomib Targets the Caspase-Like Proteasome Activity in Cervical Cancer Cells, Triggering Apoptosis That Can be Enhanced by Nelfinavir
Current Cancer Drug Targets Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Automatic Initialization of Level Set Methods in Discontinuity Regions of Liver in CT Scans
Current Medical Imaging Therapeutic Potential of Autotaxin/Lysophospholipase D Inhibitors
Current Drug Targets Synergistic Effect of the Combination of Novel Suberoylanilide Hydroxamic Acid Derivatives with Cisplatin on Anti-proliferation of Human Cancer Cells
Medicinal Chemistry Human Cancer Cell Line Based Approach of 1,3,4-thiadiazole and its Fused Ring: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry A Validated HPLC-PDA Method for the Analysis of Ursolic Acid Content in Poly(lactic acid) Nanoparticles
Current Chromatography The Mechanism of Calcitriol in Cancer Prevention and Treatment
Current Medicinal Chemistry An Efficient Cancer Classification Model for CT/MRI/PET Fused Images
Current Medical Imaging Improving the Targeting of Tubulin-Binding Agents: Lessons from Drug Resistance Studies
Current Pharmaceutical Design Catheter Related Line Sepsis Resulting from Mycobacterium <i>chelonae</i> Infection in an Immunocompromised Host
Infectious Disorders - Drug Targets Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy
Current Cancer Drug Targets The Dual Role of Tumor Necrosis Factor (TNF) in Cancer Biology
Current Medicinal Chemistry Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine Tribbles-Related Protein Family Members as Regulators or Substrates of the Ubiquitin-Proteasome System in Cancer Development
Current Cancer Drug Targets Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance
Current Pharmaceutical Design